Robert F Cornell

List of Publications by Year
in descending order

66 papers	2,879 citations	331538 21 h-index	175177 52 g-index
72 all docs	72 docs citations	72 times ranked	3513 citing authors

#	Article	IF	Citations
1	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
2	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 2019, 33, 2266-2275.	3.3	385
3	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020,	2.9	364
4	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749.	0.8	163
5	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 859-866.	0.8	140
6	Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1946-1955.	0.8	128
7	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 2901-2912.	0.8	124
8	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1154-1165.	2.3	113
9	Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 335-345.	0.2	88
10	Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. Biology of Blood and Marrow Transplantation, 2015, 21, 2061-2068.	2.0	87
11	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2019, 134, 860-860.	0.6	80
12	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	3.3	69
13	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	3.3	54
14	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.4	47
15	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. British Journal of Haematology, 2020, 190, 555-561.	1.2	36
16	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 1869-1869.	0.6	36
17	Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1368-1373.	2.0	29
18	Current Concepts of Cardiac Amyloidosis. Heart Failure Clinics, 2017, 13, 409-416.	1.0	28

#	Article	IF	Citations
19	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	3.3	27
20	Second primary malignancy after multiple myelomaâ€population trends and causeâ€specific mortality. British Journal of Haematology, 2018, 182, 513-520.	1.2	25
21	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British Journal of Haematology, 2018, 180, 271-275.	1.2	24
22	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2588-2594.	0.6	22
23	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. Frontiers in Oncology, 2019, 9, 45.	1.3	22
24	Overall survival of patients with tripleâ€class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp>. American Journal of Hematology, 2021, 96, E5-E8.	2.0	20
25	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 269-277.	2.0	19
26	Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management. Current Oncology Reports, 2019, 21, 29.	1.8	19
27	Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. Frontiers in Oncology, 2020, 10, 815.	1.3	19
28	Allogeneic Transplantation for Relapsed WaldenstrÃ¶m Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 60-66.	2.0	17
29	Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. Biology of Blood and Marrow Transplantation, 2017, 23, 529-532.	2.0	16
30	Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 205-211.	1.4	14
31	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. British Journal of Haematology, 2019, 186, 807-819.	1.2	14
32	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology, 2020, 38, 353-362.	0.8	14
33	Chemotherapy-Induced Regression of an Adrenocorticotropin-Secreting Pituitary Carcinoma Accompanied by Secondary Adrenal Insufficiency. Case Reports in Endocrinology, 2013, 2013, 1-10.	0.2	13
34	Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma. Cardio-Oncology, 2017, 3, 4.	0.8	13
35	The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis. British Journal of Haematology, 2017, 177, 481-483.	1.2	11
36	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11

#	Article	IF	Citations
37	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2022, 97, .	2.0	11
38	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. American Journal of Hematology, 2019, 94, 794-802.	2.0	10
39	KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 526-535.	0.2	10
40	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood, 2018, 132, 2015-2015.	0.6	10
41	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. Blood, 2019, 134, 3125-3125.	0.6	10
42	Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 645122.	1.1	9
43	Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decisionâ€making. American Journal of Hematology, 2016, 91, 1044-1051.	2.0	8
44	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	1.1	8
45	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1137-1146.	1.3	7
46	A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2018, 36, TPS3103-TPS3103.	0.8	7
47	Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer Medicine, 2022, 11, 358-370.	1.3	6
48	Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2017, 23, 1473-1477.	2.0	5
49	A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or NaÃ¯ve to Daratumumab (dara). Blood, 2019, 134, 1867-1867.	0.6	5
50	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. Blood, 2021, 138, 481-481.	0.6	5
51	Impact of autologous hematopoietic cell transplantation on disease burden quantified by nextâ€generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology, 2022, 97, 1170-1177.	2.0	3
52	Why WaldenstrÃ¶m macroglobulinemia is not just another indolent lymphoma. International Journal of Hematologic Oncology, 2014, 3, 95-98.	0.7	2
53	Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy. Blood, 2018, 132, 1233-1233.	0.6	2
54	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). Blood, 2015, 126, 396-396.	0.6	2

#	Article	IF	Citations
55	Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.. Journal of Clinical Oncology, 2018, 36, 8022-8022.	0.8	2
56	Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. Blood, 2021, 138, 483-483.	0.6	2
57	Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, e204-e208.	1.7	1
58	Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis. Blood, 2015, 126, 1841-1841.	0.6	1
59	Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.. Journal of Clinical Oncology, 2020, 38, 8515-8515.	0.8	1
60	Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells. BMJ Case Reports, 2019, 12, e231314.	0.2	0
61	Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL). Blood, 2011, 118, 1880-1880.	0.6	0
62	Patterns of Myeloma (MM) Progression After Autologous Transplant (AHCT) â€“ Biochemical Progression Vs. Clinical Relapse. Blood, 2011, 118, 5097-5097.	0.6	0
63	Functional improvement measured by the six-minute walk test after chemotherapy in cardiac AL amyloidosis.. Journal of Clinical Oncology, 2015, 33, e19539-e19539.	0.8	0
64	In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant. Blood, 2015, 126, 5493-5493.	0.6	0
65	Mortality of multiple myeloma diagnosed peri-hospitalization.. Journal of Clinical Oncology, 2020, 38, e20553-e20553.	0.8	0
66	Association of elevated red cell distribution width and overall survival in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8534-8534.	0.8	0